Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 2 75 IN DEXTROSE 10 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 2 75 IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINOSYN II 8.5% W/ELECTROLYTES vs TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Travasol 2.75% in Dextrose 10% provides essential amino acids and caloric support via dextrose. Amino acids serve as substrates for protein synthesis and nitrogen balance, while dextrose provides glucose for energy metabolism. The combination is used for parenteral nutrition to maintain or restore positive nitrogen balance in patients unable to tolerate enteral nutrition.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
Intravenous infusion. 1000 mL to 3000 mL per day, typically infused at 1.2-1.5 g amino acids/kg/day; adjust based on metabolic needs and fluid status.
None Documented
None Documented
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Not applicable as a single entity. Components are endogenous substances. Dextrose has a half-life of minutes due to rapid insulin-mediated uptake. Amino acids have variable half-lives (minutes to hours) depending on individual amino acid and metabolic state.
Renal >90% (as amino acids and metabolites); fecal <5%
TRAVASOL 2.75% IN DEXTROSE 10% is a combination of amino acids and dextrose. The amino acids are primarily metabolized and the nitrogen is excreted as urea in urine (renal, >90%). Dextrose is metabolized to CO2 and water; negligible biliary/fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution